日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

FOR46 (FG-3246) 是一种靶向 CD46 的免疫调节抗体药物偶联物,用于治疗转移性去势抵抗性前列腺癌患者,这是一项 I 期首次人体研究。

Aggarwal, Rahul R; Vuky, Jacqueline; VanderWeele, David; Rettig, Matthew; Heath, Elisabeth I; Quigley, David; Huang, Jiaoti; Chumber, Arun; Cheung, Alexander; Foye, Adam; Leung, Stanley; Abbey, Jill; Dorr, Andrew; Nasoff, Marc; Hunter, John; Wang, Steven; Flavell, Robert R; Fong, Lawrence; Liu, Bin; Small, Eric J

Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011

帕博利珠单抗治疗晚期尿路上皮癌患者(可能不适合接受含铂化疗)的疗效和安全性:KEYNOTE-052 和 LEAP-011 研究的事后分析

O'Donnell, Peter H; Loriot, Yohann; Csoszi, Tibor; Matsubara, Nobuaki; Shin, Sang Joon; Park, Se Hoon; Atduev, Vagif; Gumus, Mahmut; Karaca, Saziye Burcak; Grivas, Petros; de Wit, Ronald; Castellano, Daniel E; Powles, Thomas; Vuky, Jacqueline; Zhao, Yujie; O'Hara, Karen; Okpara, Chinyere E; Franco, Sonia; Homet Moreno, Blanca; Żołnierek, Jakub; Siefker-Radtke, Arlene O

CRISPRi screen uncovers lncRNA regulators of human monocyte growth.

CRISPRi筛选揭示了人类单核细胞生长的lncRNA调控因子

Flores-Arenas Cristina, Malekos Eric, Montano Christy, Covarrubias Sergio, Sudek Lisa, Dempsey Valory, Huynh Vuky, Katzman Sol, Carpenter Susan

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

一项随机、开放标签的 II 期研究,旨在评估纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药治疗高肿瘤突变负荷的晚期或转移性实体瘤患者的疗效。

Schenker, Michael; Burotto, Mauricio; Richardet, Martin; Ciuleanu, Tudor-Eliade; Gonçalves, Anthony; Steeghs, Neeltje; Schoffski, Patrick; Ascierto, Paolo A; Maio, Michele; Lugowska, Iwona; Lupinacci, Lorena; Leary, Alexandra; Delord, Jean-Pierre; Grasselli, Julieta; Tan, David S P; Friedmann, Jennifer; Vuky, Jacqueline; Tschaika, Marina; Konduru, Somasekhar; Vemula, Sai Vikram; Slepetis, Ruta; Kollia, Georgia; Pacius, Misena; Duong, Quyen; Huang, Ning; Doshi, Parul; Baden, Jonathan; Di Nicola, Massimo

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

CSF1R抑制剂治疗晚期实体瘤或腱鞘巨细胞瘤患者:Vimseltinib的I期研究

Gelderblom, Hans; Razak, Albiruni A; Taylor, Matthew H; Bauer, Todd M; Wilky, Breelyn; Martin-Broto, Javier; Gonzalez, Alejandro F; Rutkowski, Piotr; Szostakowski, Bartlomiej; Alcindor, Thierry; Saleh, Ramy; Genta, Sofia; Stacchiotti, Silvia; van de Sande, Michiel; Wagner, Andrew J; Bernthal, Nicholas; Davis, Lara E; Vuky, Jacqueline; Tait, Christopher; Matin, Bahar; Narasimhan, Supraja; Sharma, Maitreyi G; Ruiz-Soto, Rodrigo; Sherman, Matthew L; Tap, William D

Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation

不接受膀胱切除术的肌层浸润性膀胱癌患者接受放化疗的长期疗效。NRG Oncology RTOG 0524-A 1/2期临床试验的最终结果:紫杉醇联合曲妥珠单抗每日放疗或单用紫杉醇每日放疗。

Dahl, Douglas M; Karrison, Theodore G; Michaelson, M Dror; Pham, Huong T; Wu, Chin-Lee; Swanson, Gregory P; Shipley, William U; Vuky, Jacqueline; Lee, R Jeffrey; Zietman, Anthony L; Souhami, Luis; Chang, Brian K; Deming, Richard L; Ellerton, John A; Sandler, Howard M; Rodgers, Joseph P; Feng, Felix Y; Efstathiou, Jason A

Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial

来自 1/2 期 ARROW 试验的普拉替尼治疗 RET 融合阳性实体瘤患者的泛癌疗效

Subbiah, Vivek; Cassier, Philippe A; Siena, Salvatore; Garralda, Elena; Paz-Ares, Luis; Garrido, Pilar; Nadal, Ernest; Vuky, Jacqueline; Lopes, Gilberto; Kalemkerian, Gregory P; Bowles, Daniel W; Seetharam, Mahesh; Chang, Jianhua; Zhang, Hui; Green, Jennifer; Zalutskaya, Alena; Schuler, Martin; Fan, Yun; Curigliano, Giuseppe

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies

系列PARP抑制剂治疗转移性TNBC的多组学分析为合理的联合治疗提供参考

Marilyne Labrie, Allen Li, Allison Creason, Courtney Betts, Jamie Keck, Brett Johnson, Shamilene Sivagnanam, Christopher Boniface, Hongli Ma, Aurora Blucher, Young Hwan Chang, Koei Chin, Jacqueline Vuky, Alexander R Guimaraes, Molly Downey, Jeong Youn Lim, Lina Gao, Kiara Siex, Swapnil Parmar, Annet

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

帕博利珠单抗作为不适合顺铂治疗的晚期尿路上皮癌的一线疗法(KEYNOTE-052):老年患者按年龄和体能状态划分的疗效

Grivas, Petros; Plimack, Elizabeth R; Balar, Arjun V; Castellano, Daniel; O'Donnell, Peter H; Bellmunt, Joaquim; Powles, Thomas; Hahn, Noah M; de Wit, Ronald; Bajorin, Dean F; Ellison, Misoo C; Frenkl, Tara L; Godwin, James L; Vuky, Jacqueline

A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)

一项针对非膀胱切除术的肌层浸润性膀胱癌患者,在经尿道手术后接受紫杉醇联合曲妥珠单抗每日放疗或单独使用紫杉醇每日放疗的 1/2 期试验(NRG Oncology RTOG 0524 试验)

Michaelson, M Dror; Hu, Chen; Pham, Huong T; Dahl, Douglas M; Lee-Wu, Chin; Swanson, Gregory P; Vuky, Jacqueline; Lee, R Jeffrey; Souhami, Luis; Chang, Brian; George, Asha; Sandler, Howard; Shipley, William